Coherus Oncology, Inc.
Close on Oct 19, 2026
- Market cap
- $148.42M
- P/E (TTM)
- 0.7
- Dividend yield
- –
About Coherus Oncology
Biological Products, (No Diagnostic Substances), SIC 2836
Coherus Oncology, Inc. is a biopharmaceutical company that develops and commercializes immuno-oncology treatments for various cancers. Its primary commercial product is LOQTORZI, an FDA-approved immune checkpoint inhibitor prescribed for adults with advanced nasopharyngeal carcinoma. The company's clinical pipeline includes two mid-stage candidates: casdozokitug, an antibody targeting IL-27 for liver cancer and other malignancies, and tagmokitug, an antibody targeting CCR8 for solid tumors. Coherus sells LOQTORZI through wholesale specialty distributors, primarily McKesson, Cencora, and Cardinal Health, to reach healthcare providers and patients.
The company markets LOQTORZI in the United States and Puerto Rico, and licenses Canadian commercial rights to Apotex. It holds worldwide rights to casdozokitug and tagmokitug, with clinical studies underway in the United States, Canada, and other regions. Production relies on contract manufacturing organizations, with an initiative underway to onshore operations to the United States. The provided text does not disclose the location of the company's headquarters.
Summary of the business section of Coherus Oncology's latest annual report, written by StockData.
Company profile
Company
- Legal name
- Coherus Oncology, Inc.
- Founded
- 2010
- Headquarters
- Redwood City, CA
- Address
- C/O Dennis M. Lanfear, 333 Twin Dolphin Dr, Suite 600 94065
- Phone
- (650) 649-3530
- Website
- www.coherus.com
- Employees
- 147, Dec 31, 2025
- Industry
- Biological Products, (No Diagnostic Substances)
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
- Auditor
- Ernst & Young LLP, San Francisco, California
Stock & identifiers
- Ticker
- CHRS
- Exchange
- Nasdaq
- IPO date
- Nov 6, 2014
- Shares outstanding
- 155M, Jul 31, 2026
- Public float
- $81.90M, Jun 30, 2025
- Filer category
- Accelerated filer<br>Smaller reporting company
- SEC CIK
- 1512762
- CUSIP
- 19249H103
- ISIN
- US19249H1032
- LEI
- 5493007IL8W5MV932D26
- EIN
- 27-3615821
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Dennis M. Lanfear | President & CEO, Director | 1,567,884 |
| Bryan J. McMichael | Chief Financial Officer | 133,736 |
| Paul Reider | Chief Commercial Officer | 82,069 |
| Ali J. Satvat | Director | 30,000 |
| Lee Nisley Newcomer | Director | 30,000 |
| Jill O'Donnell-Tormey | Director | 30,000 |
| Charles W. Newton | Director | 30,000 |
| Rita A. Karachun | Director | 30,000 |
| Mats Wahlstrom | Director | 30,000 |
| Michael Lee Ryan | Director | 30,000 |
| Georgia Erbez | Director | – |
CEO pay and shareholder return
Pay versus performance table from the proxy statement
| Fiscal year | CEO total pay | CEO pay actually paid | Other executives (avg) | Value of $100 invested | Peer group |
|---|---|---|---|---|---|
| FY2025 Mr. Dennis Lanfear | $2.74M | $2.84M | $1.17M | $18 | – |
| FY2024 Mr. Dennis Lanfear | $4.80M | $2.36M | $1.35M | $17 | – |
| FY2023 Mr. Dennis Lanfear | $5.90M | $1.73M | $1.86M | $42 | – |
| FY2022 Mr. Dennis Lanfear | $6.87M | $212.83K | $2.12M | $50 | – |
| FY2021 Mr. Dennis Lanfear | $8.59M | $6.46M | $2.45M | $-11 | $25 |
| FY2020 Mr. Dennis Lanfear | $7.28M | $8.38M | $2.04M | $-3 | $26 |
“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.
Employees
Headcount reported in annual reports
“As of December 31, 2025, we had 147 full-time and part-time employees, which represented a decrease of 81 full-time and part-time employees since December 31, 2024.”
Corporate history
Events identified from SEC filings